ERRATUM  by unknown
41. Ludwig MS, Goodman M, Miller DL, Johnstone PAS. Postoperative
survival and the number of lymph nodes sampled during resection of
node-negative non-small cell lung cancer. Chest 2005;128:1545–1550.
42. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is
associated with decreasing ratio of metastatic to examined lymph nodes.
J Clin Oncol 2005;23:8706–8712.
43. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative
lymph node count is independently associated with improved long-term
survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006;24:
3570–3575.
44. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node
dissection improves survival in patients with stages II and IIIa non-small
cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac
Surg 2000;70:358–65; discussion 365–366.
45. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for
non-small cell lung cancer: systematic review and meta-analysis of
randomised controlled trials. Thorax 2006;61:597–603.
46. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H.
Patients with stage I non-small cell lung carcinoma at postoperative risk
for local recurrence, distant metastasis, and death: implications related to
the design of clinical trials. Int J Radiat Oncol Biol Phys 1999;45:315–
321.
47. Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and
lymphatic vessel invasion in resected nonsmall cell lung carcinoma.
Correlation with TNM stage and disease free and overall survival.
Cancer 1996;78:2111–8.
48. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic
prognostic factors in surgically resected nonsmall cell lung carcinoma. A
comparison of prognostic factors for each pathologic TNM stage based
on multivariate analyses. Cancer 1999;86:1976–1984.
49. Gabor S, Renner H, Popper H, et al. Invasion of blood vessels as
significant prognostic factor in radically resected T1-3N0M0 non-small-
cell lung cancer. Eur J Cardiothorac Surg 2004;25:439–442.
50. Onn A, Choe DH, Herbst RS, et al. Tumor cavitation in stage I
non-small cell lung cancer: epidermal growth factor receptor expression
and prediction of poor outcome. Radiology 2005;237:342–347.
51. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are
independent prognostic factors in stage I non-small-cell lung cancer. Int
J Radiat Oncol Biol Phys 2002;52:1047–1057.
52. Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson
score in resected stage I nonsmall cell lung cancer. Eur Respir J
2005;26:480–486.
53. Ambrogi V, Pompeo E, Elia S, Pistolese GR, Mineo TC. The impact of
cardiovascular comorbidity on the outcome of surgery for stage I and II
non-small-cell lung cancer. Eur J Cardiothorac Surg 2003;23:811–817.
54. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on
survival after surgical resection in patients with stage I non-small cell
lung cancer. J Thorac Cardiovasc Surg 2002;123:280–287.
55. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987;40:373–383.
56. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial
comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients
with advanced non-small-cell lung cancer: a cooperative multinational
trial. Ann Oncol 2002;13:1539–1549.
57. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus vinorel-
bine plus cisplatin for advanced non-small-cell lung cancer: the TAX
326 study group. J Clin Oncol 2003;21:3016–3024.
58. Schabel FM. Rationale for adjuvant chemotherapy. Cancer 1977;39:
2875–2882.
59. Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Breast
cancer: achievements in adjuvant systemic therapies in the pre-genomic
era. Oncologist 2006;11:111–125.
60. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine
prognosis in early-stage non-small-cell lung cancer. N Engl J Med
2006;355:570–580.
61. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour
subsets in non-small-cell lung cancer. Lancet 2003;362:433–439.
62. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N Engl J Med 2006;355:983–991.
63. Montgomery K. How Doctors Think: Clinical Judgment and the Practice
of Medicine. New York: Oxford University Press, 2006.
ERRATUM
Wang SJ, Fuller CD, Thomas CR Jr. Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer. J Thorac Oncol
2006;2(3):180–190.
In the original research article entitled “Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer”, [1] which appeared in
the March 2007 issue of the Journal of Thoracic Oncology, the Figure 1 caption stated that the slope of the survival curve represented the instantaneous
hazard rate. In actuality, the slope of the survival curve, St, represents the negative of the probability density function, ft, the probability of an event
occurring at time t [2], which can be written as:
dSt
dt   ft
The hazard rate, t, the instantaneous rate of occurrence of an event at time t, is actually defined as the probability density at time t divided by the survival
at time t:
t
ft
St
The subsequent conditional survival calculations in the article remain unchanged.
The authors are grateful to John Crowley, PhD, Director of the Southwest Oncology Group Statistical Center, for bringing this correction to our attention.
1. Wang SJ, Fuller CD, Thomas CR. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol 2007;
2(3):180–190.
2. Tableman M, Kim JS. Survival analysis using S: Analysis of time to event data. 1st ed. Chapman & Hall/CRC; 2003.
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